Clinical Specialties Compounding Pharmacy
FDA inspection history in Augusta, Georgia, 2013 to 2014
- 1
- Warning letter
- 1
- Form 483
Every document, by year
- Warning letter
- Form 483
2013: one Form 483; 2014: one warning letter.
The story so far
Built from the dates and citations on the documents themselves.
- 2013–14One Form 483 and one warning letter, at Augusta, Georgia.
Cited most
Across all Clinical Specialties Compounding Pharmacy observations on file
- 21 CFR 211.42(b)Design and construction features3
- 21 CFR 211.165(a)Testing and release for distribution2
- 21 CFR 211.25(a)Personnel qualifications2
- 21 CFR 211.113(b)Control of microbiological contamination1
- 21 CFR 211.150(b)Distribution procedures1
The complete Clinical Specialties Compounding Pharmacy file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Augusta, Georgia
One warning letter and one Form 483 · 2013 to 2014 · 11 observations
Latest: Warning letter, Jun 27, 2014 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2014-06-27 | Warning letter Warning letter | Augusta, Georgia | — | $99 |
| 2013-04-02 | 483 Form 483 | Augusta, Georgia | 11 | $99 |
Investigators on these documents
FEI number 3010078541 · most recent document Jun 27, 2014
About Clinical Specialties Compounding Pharmacy
How many FDA Form 483s has Clinical Specialties Compounding Pharmacy received?
FDA Intel has 1 Form 483 on file for Clinical Specialties Compounding Pharmacy; the most recent is dated Apr 2, 2013.
When was Clinical Specialties Compounding Pharmacy last inspected by FDA?
The most recent FDA inspection document on file for Clinical Specialties Compounding Pharmacy is a Form 483 dated Apr 2, 2013, for the site in Augusta, Georgia.
What did FDA cite at Clinical Specialties Compounding Pharmacy?
The regulations cited most in the observations on file for Clinical Specialties Compounding Pharmacy are 21 CFR 211.42(b) (Design and construction features), 3 times; 21 CFR 211.165(a) (Testing and release for distribution), 2 times; 21 CFR 211.25(a) (Personnel qualifications), 2 times.
Has Clinical Specialties Compounding Pharmacy received an FDA warning letter?
Yes. FDA Intel has 1 FDA warning letter on file for Clinical Specialties Compounding Pharmacy; the most recent is dated Jun 27, 2014.